Skip to main content
. 2023 Aug 17;29(2):142–150. doi: 10.1093/oncolo/oyad231

Figure 4.

Figure 4.

Empirical mean change from baseline to week 104 in (A) EORTC QLQ-C30 GHS/QoL, (B) EORTC QLQ-C30 physical functioning, and (C) FKSI-DRS. CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms; GHS, global health status; QoL, quality of life.